
Opinion|Videos|April 4, 2025
Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy
Experts discuss why it is critical to have standardized protocols in place for managing cytokine release syndrome (CRS) in patients receiving bispecific antibodies, outlining the key components of an effective CRS management protocol as well as best practices for transitions of care between settings when administering and managing bispecifics.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Why is it critical to have standardized protocols in place for managing CRS in patients receiving bispecific antibodies?
- What are the key components of an effective CRS management protocol?
- What are best practices for transitions of care between settings when administering and managing bispecifics?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NIH Grant Terminations Disrupt 1 in 30 Clinical Trials, Impacting Over 74,000 Participants
2
How Effective and Safe Are GLP-1s for Weight Loss?
3
Rescue Therapy With Rozanolixizumab Promising in Triple-Seronegative MG
4
FDA Approves Plozasiran to Reduce Triglycerides in Familial Chylomicronemia Syndrome
5
















































